Holen Sie sich die Stockscreener-App
0.3266
0.00%
0.00
Vorhandelsmarkt:
.33
0.0034
+1.04%
Schlusskurs vom Vortag:
$0.3266
Offen:
$0.326
24-Stunden-Volumen:
213.32K
Relative Volume:
0.08
Marktkapitalisierung:
$29.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-166.14M
KGV:
-0.1701
EPS:
-1.92
Netto-Cashflow:
$-139.92M
1W Leistung:
+0.18%
1M Leistung:
+35.97%
6M Leistung:
-75.07%
1J Leistung:
-67.66%
1-Tages-Spanne:
$0.326
$0.3275
1-Wochen-Bereich:
$0.3211
$0.328
52-Wochen-Spanne:
$0.2157
$1.555
Allakos Inc Stock (ALLK) Company Profile
Firmenname
Allakos Inc
Sektor
Branche
Telefon
650-597-5002
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS, CA
Vergleichen Sie ALLK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALLK
Allakos Inc
|
0.3266 | 29.37M | 0 | -166.14M | -139.92M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Allakos Inc Stock (ALLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-17 | Herabstufung | Jefferies | Buy → Hold |
| 2024-01-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-18 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-08 | Fortgesetzt | Jefferies | Buy |
| 2023-09-27 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-05-12 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-07 | Eingeleitet | Piper Sandler | Overweight |
| 2022-09-12 | Herabstufung | SMBC Nikko | Neutral → Underperform |
| 2021-12-22 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-22 | Herabstufung | Cowen | Outperform → Market Perform |
| 2021-12-22 | Herabstufung | Jefferies | Buy → Hold |
| 2021-12-22 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-12-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-07-15 | Eingeleitet | Cowen | Outperform |
| 2021-05-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-15 | Eingeleitet | BofA Securities | Buy |
| 2020-12-21 | Eingeleitet | SVB Leerink | Outperform |
| 2020-02-27 | Eingeleitet | Barclays | Underweight |
| 2020-02-04 | Fortgesetzt | Goldman | Neutral |
| 2018-08-13 | Eingeleitet | Goldman | Neutral |
| 2018-08-13 | Eingeleitet | Jefferies | Buy |
| 2018-08-13 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Allakos Inc Aktie (ALLK) Neueste Nachrichten
Press Release Distribution & PR Platform - ACCESS Newswire
Checking in on Allakos Inc (ALLK) after recent insiders movement - knoxdaily.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, HMST, ALLK, OPOF on Behalf of Shareholders - PR Newswire
Allakos Inc (ALLK) Recovers 48.96% From Low: Are We There Yet? - stocksregister.com
Allakos And 2 Other Promising Penny Stocks To Watch - simplywall.st
Short Interest in Allakos Inc. (NASDAQ:ALLK) Decreases By 13.9% - Defense World
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc.ALLK - PR Newswire
Concentra Biosciences, LLC entered into an agreement to acquire Allakos Inc. for $31 million. - marketscreener.com
Allakos Inc Inc. (ALLK) Price Performance: A Technical Analysis Perspective - investchronicle.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Allakos, Inc. (ALLK) - TradingView
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Tang Capital’s Concentra nabs a win, making a deal to buy Allakos - Endpoints News
Allakos to be acquired by Concentra Biosciences for 33c per share in cash - TipRanks
ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders - The Joplin Globe
Allakos to Be Acquired by Concentra Biosciences for $0.33 per Share - MarketScreener
Allakos Announces Merger Agreement with Concentra Biosciences - TipRanks
Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders - Bluefield Daily Telegraph
Allakos agrees to Concentra Biosciences acquisition - Investing.com
Allakos surges on reverse merger deal with Concentra Biosciences - Seeking Alpha
Allakos to Be Acquired for 33 Cents a Share - MarketWatch
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share - The Manila Times
Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences - MarketScreener
Allakos (ALLK) Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share - StreetInsider
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in - Bluefield Daily Telegraph
Biotech Deal Alert: Concentra Biosciences Acquires AllakosKey Terms Revealed - Stock Titan
ALLK ALERT: ROSEN, A LEADING FIRM, Reminds Allakos Inc. Investors of Important May 11th Deadline in Securities Class Action First Filed By Firm- ALLK - ACCESS Newswire
Allakos stock plunges to 52-week low of $0.23 amid market challenges By Investing.com - Investing.com South Africa
Allakos stock plunges to 52-week low of $0.23 amid market challenges - Investing.com Australia
Shareholder Alert: The Ademi Firm Investigates Whether LENSAR, Inc. is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
Allakos Inc. (NASDAQ:ALLK) Short Interest Update - Defense World
Analyzing Allakos (NASDAQ:ALLK) and Acerus Pharmaceuticals (OTCMKTS:TRLPF) - Defense World
Allakos Inc.: Hold Rating Amid Restructuring and Financial Uncertainty - TipRanks
Allakos faces potential Nasdaq delisting over share price By Investing.com - Investing.com India
Allakos Reports Q4 2024 Results Amid Strategic Shift - TipRanks
Allakos faces potential Nasdaq delisting over share price - Investing.com
Allakos Inc. (ALLK) reports earnings - Quartz
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results - The Manila Times
Allakos Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Allakos Swings to Surprise Q4 Profit as Major Restructuring Takes Shape - StockTitan
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Allakos (ALLK) Projected to Post Quarterly Earnings on Thursday - Defense World
The Curious Case of Allakos - substack.com
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Losses to Contact Its Attorneys: 3 DAY APPLICATION DEADLINE ALERT - ACCESS Newswire
Allakos Inc. (ALLK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Lee joins Lycia as CMO - BioCentury
It is Poised to be a Bull Market for Allakos Inc (ALLK) - SETE News
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm - EIN News
Introducing Our Rant Against Allakos Inc - US Post News
FY2024 EPS Estimates for Allakos Lowered by Leerink Partnrs - Defense World
Allakos Inc [ALLK] Officer makes an insider purchase of 21,116 shares worth 23219.0. - Knox Daily
Finanzdaten der Allakos Inc-Aktie (ALLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):